Physician profile
Amanda S Gahsman
NPI 1558747493
$1,969.46
in general payments reported to CMS, 2019-2025
31 companies · $383 in 2025
The $383 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $317 · 2022: $491 · 2023: $513 · 2024: $266 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,162.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $370.39 | 2021-2025 | |
| Aspira Women'S Health INC | $253.52 | 2023-2025 | Ova1 |
| Biogen, INC. | $204.12 | 2024-2025 | Zurzuvae |
| Astellas Pharma US INC | $155.18 | 2023-2025 | Veozah |
| Scynexis, INC. | $101.27 | 2022 | |
| Therapeuticsmd, INC. | $88.97 | 2022 | |
| Coopersurgical, INC. | $83.99 | 2022-2025 | Paragard T 380a, Paragard T 380a |
| Daiichi Sankyo INC. | $71.46 | 2022-2023 | Injectafer |
| Davol INC. | $63.33 | 2023 | Arista Ah Flexitip |
| Pfizer INC. | $61.75 | 2021-2025 | |
| Exeltis, USA INC. | $55.59 | 2021-2025 | Slynd |
| Hologic Sales and Service, LLC | $47.64 | 2025 | Fetal Fibronectin Enzyme Immunoassay, Sonata Sonography-Guided Transcervical Fibroid Ablation System, Acessa Provu System |
| Merck Sharp & Dohme LLC | $39.90 | 2024-2025 | Gardasil 9, Gardasil, Capvaxive |
| Mylan Pharmaceuticals INC. | $32.42 | 2021-2022 | |
| Smith+Nephew, INC. | $30.33 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $23.48 | 2022 | |
| Organon LLC | $23.46 | 2022 | |
| Axonics, INC. | $23.02 | 2023 | Axonics |
| Ardelyx, INC. | $21.78 | 2025 | Ibsrela |
| Evofem Biosciences, INC. | $21.26 | 2022 | |
| Alexion Pharmaceuticals, INC. | $20.83 | 2022 | |
| Convatec INC. | $19.66 | 2021 | |
| Gynesonics, INC. | $19.60 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Shield Therapeutics INC | $18.82 | 2022 | |
| Amgen INC. | $18.33 | 2024 | Prolia, Evenity |
| Mayne Pharma Commercial LLC | $17.69 | 2023 | |
| Minerva Surgical, INC | $17.59 | 2021 | |
| Ethicon US, LLC | $17.13 | 2021 | |
| Sage Therapeutics, LLC | $16.36 | 2022 | |
| Novo Nordisk INC | $16.07 | 2024 | Wegovy |
| Lilly USA, LLC | $14.52 | 2025 | Zepbound, Trulicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Gahsman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.